February 2015 Volume 11, Issue 2
Volume 11, Issue 2 | February 2015
February 2015
In this Issue
Business & Government Policy
Shire to snap up NPS Pharma for $5.2B
Acquisition is a further step by Shire toward building itself into a leading biotech$25-million launch for Vtesse
Company to work with NIH on drugs for Niemann-Pick disease and other life-threatening rare diseasesConverging on growth
Biogen Idec expands pain portfolio with Covergence expertise, Phase 2 drug candidateFor your approval
A collection of recent regulatory approvals and actions globallyOn the cutting edge
A roundup of instrumentation, software and other tools and technology newsResearch & Development
Roche teams with Foundation Medicine
Molecular information collaboration leverages companies’ strengths to advance progress of personalized treatments for oncologyImmune checkpoint strides
Research indicates cancer immunotherapies have potential for a long-lasting response to treatmentSequencing for success
Roche acquires Bina Technologies, enters genomic informatics marketAdding to the mix
Rockland ventures into aptamer market with SBIR fundingLiving Lab expands
FEI and OHSU install complete correlative microscopy workflow in newly built collaborative science facilitySpecial Reports
Signs of intelligent biomarkers
Lots of genomics data, but how much knowledge?Feature
Pittcon 2015 provides breadth and depth
Pittcon maintains its reach into pharma, biotech and life sciences while adding a new focus on a younger demographicQ&A
Q&A: Opioid addiction and the quest for a solution
DDNews talks with Dr. Mark A. Sirgo, of BioDelivery Sciences Inc. about how his company and its collaborator Endo Pharmaceuticals are working together to help resolve the problem of addiction to narcotic painkillersEditor's Focus
Entering the 21st century…precisely?
Congress and President Obama are both talking big talk about stepping into the 21st century boldly in terms of healthcare, but what are they really telling us and what will they actually do?Commentary
The tyranny of averages
There are plenty of numbers in the life-sciences, pharma and the like, but we need to look for more meaning and context for themA grad student Q&A with Peter T. Kissinger
What 'Dear Abby' did for relationship advice and other wisdom about life, DDNews columnist Peter T. Kissinger seeks to do with a Q&A-style piece aimed at answering some of the (presumably) pressing concerns of grad students and postdocsClinical Trials
Taking aim at AT
Alnylam reports encouraging Phase 1 results for hemophilia RNAi therapeuticA new class of opioid therapeutic
Cara Therapeutics reports positive top-line data from Phase 1b trial of IV CR845 in dialysis patients with uremic pruritusStudies in motion
Auspex scores in three clinical trials involving SD-809Arresting cardiac risks
FDA gives go-ahead for earlier cardiac safety testingReal talk on RASAL2
GIS study finds RASAL2 to be upregulated in triple-negative or estrogen receptor-negative breast cancer tumorsDiscovery
Enzyme provides an inroad
Scientists at Scripps discover enzyme for treating brain inflammation in patients with PHARC, Parkinson’s, Alzheimer’s, ALS and MSMersana and Takeda expand ADC partnership
Aim is to create novel Fleximer antibody-drug conjugate candidates to include additional oncology-relevant targetsExploring Ebola efforts
Kymab to lead a consortium to pursue antibodies against Ebola virusPreclinical
Repurposed duo vs. Alzheimer’s
Pharnext’s pleotherapy shows synergistic effects in PXT-864 for Alzheimer’s diseaseAttacking an early MS sign
Collaboration keeps first-in-class neuroprotective agent in acute optic neuritis on track for early clinical trialsRebranding and reaching out
Expansion, conference are milestones for Crown BiosciencePharma strikes sweet deal with Hershey company
Cipher pays $500K for assets of Melanovus; expands dermatology pipelineDiagnostics
Two deals; one goal
Amarantus expands its reach with acquisition deal and license agreementRevolution in immuno-oncology
Intratumoral cancer immunotherapy enhances local delivery and uptake of DNA-based immune-targeting agentsMassing diagnostic efforts in Massachusetts
Diagnostics For All issues challenge grant for multi-institution Ebola partnershipFirst to assess BRCA status
Myriad receives FDA approval on companion diagnostic for Lynparza in ovarian cancer
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
A closer look at the tumor microenvironment
New technologies are allowing researchers to delve deeper into the complex tumor landscape.
Exploring stain-free western blotting
Researchers can achieve seamless western blot experiments by implementing advancements in stain-free technology, normalization methods, and compliance integration.
Streamlining biopharmaceutical analysis with digital solutions
Discover how digitization improves data integrity and accelerates decision-making in biotherapeutics development.
